Beigene

Q2 FY2026 EarningsH1 FY26 R&D investment surged to $1.15B, a 14.6% YoY increase driven by early-stage pipeline expansion and collaboration projects. While zanubrutinib and tislelizumab R&D normalized, investments in BCL2 and CDK4 inhibitors grew significantly. The company maintains a high-intensity R&D strategy, though GAAP EPS ($1.63) and Revenue ($1.62B) for Q2 must be monitored against the high consensus mean to confirm commercial ramp-up efficiency.